Loading...
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
Duvelisib (Copiktra(®)) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma...
Saved in:
| Published in: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6631818/ https://ncbi.nlm.nih.gov/pubmed/31064155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12020069 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|